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ABSTRACT 
Fibrosarcoma is a deadly disease in cats and is most often located at classical vaccine 
injections sites.  More rare forms of spontaneous non-vaccination site (NSV) fibrosarcomas have 
been described and have been found associated to genetic alterations.  
Purpose of this study was to compare the efficacy of adenoviral gene therapy in NVS 
fibrosarcoma.  The NVS fibrosarcoma cell line (Cocca-6A) was isolated from a spontaneous 
fibrosarcoma that occurred in a domestic calico cat. Cocca-6A fibrosarcoma cells were 
morphologically and cytogenetically characterized.  The feline cells were karyotyped and their 
chromosome number was counted using a Giemsa staining. Giemsa block staining of metaphase 
spreads of the Cocca-6A cells demonstrated deletion of one of the E1 chromosomes, where feline 
p53 maps.  Adenoviral gene therapy demonstrated a remarkable effect on the viability and growth 
of the Cocca-6A cells following transduction with adenoviruses carrying RB/p105, Ras-DN, 
Mda-7/IL-24 or their combination. Adenoviral gene transfer was verified by western blot 
analysis.  Flow cytometry assay and Annexin-V were used to study cell-cycle changes and cell 
death of transduced cells. 
Therapy for feline fibrosarcomas is often insufficient for long lasting tumor eradication. 
The use of Ad.Ras-DN, Ad.Rb/p105 and Ad.Mda7/IL-24 has been identified as a gene therapy 
for a possible future adjuvant treatment in spontaneous feline fibrosarcoma.  More gene therapy 
studies should be conducted in order to understand if these viral vectors could be applicable 
regardless the origin (spontaneous vs. vaccine induced) of feline fibrosarcomas. 
 
 
 
Chapter I: INTRODUCTION 
1.1 Feline Fibrosarcoma 
Domestic animal sarcomas are poorly characterized neoplasms. They arise from primitive 
mesenchymal cells and can differentiate into different cell types. One such type is fibrosarcoma, 
derived from the fibrous connective tissue with the presence of undifferentiated proliferating 
fibroblasts in a collagen matrix and mostly spindle shaped. Spindle cell carcinomas of domestic 
animals are mostly superficial in location and benign. But some rapidly growing and hyper 
vascular tumors can be malignant [2]. Thus they need to be treated aggressively. 
Fibrosarcoma represents 6-12% of all feline tumors [3] and third most common skin 
tumor in cats.  Fibrosarcomas vary markedly in their appearance and size. Neoplasms arising in 
the dermis may appear nodular (Fig. 1). Those arising in the subcutaneous fat (Fig.1) or subjacent 
soft tissues may require palpation to identify. They appear as firm, flesh lesions involving the 
dermis and subcutaneous fat (Fig. 1) and often invade musculature along the fascial planes [2]. 
Fibrosarcomas in cats can be caused by feline leukemia virus (FeLV), be associated with 
vaccination injection sites, or develop spontaneously.  
  
Figure 1: On the left a diagram illustrating the different dermal layers. On the right, a diagram 
showing the growth of fibrosarcoma and its penetration of the dermal layers. (Adapted from 
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http://www.vcahospitals.com/main/pet-health-information/article/animal-health/fibrosarcoma-
and-spindle-cell-tumors-in-dogs/268) 
An epidemiologic analysis showed correlation between fibrosarcoma and injection sites 
for leucosis vaccines [4].  The vaccines generally associated with this disease have been the 
adjuvant rabies and feline leukemia virus vaccines; however, association with non-adjuvant 
vaccines has been occasionally reported [4].  Aluminum (commonly used in adjuvants) has been 
identified in vaccine-induced fibrosarcomas, and a prolonged proliferation of fibroblasts in 
response to the adjuvant may predispose them to undergo neoplastic transformation [2]. 
Spontaneous fibrosarcomas are a solitary form common in older cats [2]. These 
neoplasms originate in the dermis or the subcutis (Fig. 1). They predominantly are locally 
invasive and appear to have low metastatic potential on first presentation. They are not associated 
with FeLV virus. More rare forms of spontaneous fibrosarcoma have been described and have 
been found associated to genetic alterations, such as allelic loss, point mutations and 
translocations [5, 6]. 
Surgery is the typical therapeutic treatment followed if needed by iridium radiotherapy.   
Despite the effectiveness of this treatment, there is high neoplasm recurrence on the primary 
tumor site [7] as fibrosarcomas could infiltrate along the facial planes and reinitiate the tumors. 
Thus wide excision or amputation is performed when anatomically feasible [2]. Several studies 
reported the low efficiency of chemotherapy by itself [8, 9].  Due to poor cure rates with surgery 
alone, the additional use of adjuvant radiation therapy and/or chemotherapy has been under 
investigation at multiple veterinary cancer centers for the last few years [10, 11]. Recently, it has 
been suggested that the use of a tri-modal therapeutic approach (radical surgery, radiation therapy 
and chemotherapy) will very likely be the preferred therapy for this extremely malignant tumor 
[11].  Other options that are being explored encompass gene therapy, including 
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immunostimulatory gene therapy, which constitutes the most promising treatments.   
 
1.2 Gene Therapy 
Cancer is predominantly a genetic disease with aberrant gene expression that develops 
due to various reasons including inherited or acquired gene gain, loss or mutation as cells become 
malignant [12]. This altered gene expression may affect normal cellular functions, leading to the 
phenotypic and characteristic changes associated with malignancy such as increased proliferation, 
invasion and the ability to metastasize [12]. Thus by restoring or replacing the faulty gene it is 
possible to reverse, arrest or delay this progression [12].  
Gene therapy aims to cure a disease by providing specific cells of the patient with novel 
genetic information. In general, it consists of introducing new genes in cells to replace a missing 
or defective gene or to express a therapeutic protein [13]. Strategies for cancer gene therapy 
include (i) introduction or (re)activation of tumor suppressor genes, (ii) inactivation of oncogenes 
and (iii) introduction of genes that lead to expression of enzymes, toxic proteins or that activate 
the immune system [14]. During the past ten years, several diverse tools have been developed to 
transport a therapeutic gene to the site of interest. These so-called gene-transfer vehicles can be 
divided into two subgroups: viral and non-viral vehicles [13]. 
Non-viral vehicles are suitable due to their lack of inducing a specific immune response, 
simplicity, packaging capacity and potential for large-scale production. The simplest form of non-
viral gene therapy is direct injection of naked DNA at the site of interest [13]. Non-viral gene 
delivery can also be achieved by using lipoplex vehicles, liposomes, polymer-based vehicles, 
recombinant plasmids etc. 
Viruses for gene therapy can be classified into two major groups based on their ability to 
4 
 
integrate their genetic material into the genome of the host: (i) integrating viruses (e.g. retrovirus 
and lentivirus), which induce stable expression of the transgene and are transmitted to all the 
progeny of transduced cells; and (ii) non-integrating viruses (e.g. adenovirus and herpesvirus), 
which only induce transient expression. In the latter case, it might be necessary to repeat viral 
administration, which increases the risk of eliciting an immune response against the virus [13]. 
Our study focuses on the use of adenoviruses against the Cocca-6A cell line. 
Recent scientific reports have used gene therapy to stimulate immune responses in feline 
fibrosarcoma [7, 15].  Recombinant plasmids coding IL-2, IFN-γ, and GM-CSF have been used in 
phase-I studies using intratumoral magnetofection [16].  Additionally, cats and dogs treated with 
repeated local injections of engineered histo-incompatible cells secreting high levels of human 
interleukin-2 (hIL-2) to the tumor site relapse less frequently and survive longer than control 
animals treated by surgery and radiotherapy alone [17].  Recently, viral vectors expressing feline 
or human IL2, respectively, were administered to domestic cats and showed a 33% reduction of 
tumor recurrences in cats receiving either human IL2 or feline IL2 [7]. Thus gene therapy is a 
promising strategy in treating feline cancers.  
 
1.2.1 Adenoviruses 
 Adenoviruses (Ads) are relatively promiscus in their ability to infect wide range of 
species and tissues [18]. They are one of the most-efficient viral vectors for transgene expression. 
Based on their cell-surface antigens, adenoviruses are divided in many different serotypes that 
have different natural tropism. In most gene therapy studies, serotype 5 has been used because it 
has a high efficiency of gene transfer in vivo and its biology is well known [13].  
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Figure 2. Schematic representation of viral life cycle.  (Adapted from Chiocca, E.A. Nat Rev 
Cancer, 2002 [1].) 
 The life cycle of adenovirus can be divided into several stages (Fig. 2). During the 
infection stage, virus surface proteins, such as adenovirus fibre attach to cellular receptor such as 
coxsackie adenovirus receptor (CAR) or infect through endocytosis [1] (Fig. 2). CAR is a 
member of immunoglobulin family with two extracellular domains that is present in intracellular 
junctions such as cardiac intercalated disc and tight junctions of polarized epithelial cells [18]. 
Once inside the cell, the virus expresses several gene products that target cellular proteins and 
modulate several cellular processes, such as preventing apoptosis or inducing cell cycle entry. 
These promote viral replication and production of viral proteins that eventually lead to cell lysis 
and release of viral progeny. Each step is mediated by a diverse group of proteins such as E1A, 
E1B, E3 and E4 [1]. 
 Cancer gene therapy classically involves delivery of tumor suppressor, apoptosis-
inducing or suicide genes directly into tumor cells [19, 20]. Replication incompetent adenoviral 
(Ad) vectors are frequently used for this application because they promote high-level transgene 
expression [20, 21]. The E1 deletion renders the recombinant virus replication-defective, and thus 
provides an important safety feature [22]. To achieve a discernible and significant antitumor 
response mandates administering the Ad multiple times, which can provoke an immune response 
that mediates viral clearance [20, 21]. Most of the adenoviruses used in this study were 
replication incompetent adenoviruses. 
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 Conditionally replication competent adenoviruses (CRCAs) are effective in killing cancer 
cells by replication, thus requiring fewer administrations [23]. Ad early proteins, E1A and E1B, 
facilitate cell transformation by their capacity to induce cell cycle progression through the S-
phase and provide protection from apoptosis consequently allowing viral replication to occur 
[24]. The CRCAs we used is also called cancer terminator virus (CTV). In CTVs PEG-promoter 
drives the expression of E1A and E1B genes thus ensuring cancer specific replication while 
CMV-promoter regulates the expression of either mda-7/IL-24 or IFN-γ in the E3 region of the 
adenovirus [21]. These CRCAs do not harm normal cells but induce oncolysis by adenoviral 
replication and diverse tumor-suppressor effects of the expressed transgene [21]. CRCAs embody 
several attributes that support their utility as oncolytic agents including a lytic replication cycle, 
high stability, efficient genome transfer and low pathogenicity [25, 26]. Moreover, the technology 
for Ad production at high titers is well established and Ad structure, genome and replication cycle 
are well characterized, facilitating the engineering of these viruses for therapeutic purposes [21, 
25, 26]. Anti-Ad neutralizing antibodies significantly attenuate the activity of a replication-
incompetent Ad but have limited or no effect on the activity of a replication-competent Ad [27]. 
 
1.3 Cocca Clinical Data 
 10 year-old domestic calico female cat presented with a rapidly growing lesion on the 
first digit of the left front paw that became ulcerated and started bleeding within 3 weeks from the 
first observation.  The tumor formation was surgically removed in March 2007 at the Martin’s 
Veterinarian Clinic in Ashland, Kentucky and it was histologically diagnosed as a fibrosarcoma 
that appeared to be completely excised.  No chemo- or radiation-therapy was given. Tumor 
recurred within 15-days from the first operation and appeared to grow at a faster rate, doubling its 
size in the matter of one week.  The cat was amputated of the diseased limb and a biopsy of the 
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recurred tumor was collected in a sterile 50-mL tube containing sterile cold isotonic saline 
solution.  Recurred tumor was sent to a veterinarian pathology laboratory to reconfirm the 
histological diagnosis. 
          
Figure 3. A 200X enlargement of the H&E staining for a histological cross-section of the feline 
pathologic specimen. Optical microscope of the neoplastic tissue shows cells that appear to have 
indistinct cell borders, round to oval nuclei with finely stippled chromatin, and small single or 
multiple nucleoli. 
The pathology report described the presence of an irregular dermal-subdermal mass of 
sheets and streams of spindle cells and small amounts of collagenous stroma, which is compatible 
with a diagnosis of fibrosarcoma (Fig. 3).  The cells appeared to have indistinct cell borders, 
round to oval nuclei with finely stippled chromatin, and small single or multiple nucleoli. The 
cells had a mitotic index of 12/10 high power fields. 
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1.3.1 Establishment of Cocca 6A 
 The biopsy was minced and dissociated within an hour to obtain cells for a primary 
culture. Cells able to attach and survive showed a typical fibroblast aspect forming various clones 
of the feline primary culture (Figs. 4 A-E).  The clone Cocca-6A after 3 months of continuous 
culture started growing rapidly and the cells appeared homogeneous in size (Fig. 4 F). The 
morphology of the Cocca-6A cells remained unchanged after 6, 12 months (Figs. 4 G and H), still 
remains unchanged after 2 years and over 200 passages of continuous culture (Fig. 4 I). The 
Cocca-6A cells showed a serum dependent growth and did not form colonies in soft agar. We 
characterized the growth of the Cocca-6A cell line and found that at serial passage 135 the cells 
maintained a fibroblastic appearance. Additionally, we observed that at passage one hundred, 
there was a population doubling time of approximately 27 hours. 
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Figure 4. Establishment of a feline fibrosarcoma cell line.  (A-E) Phase contrast imaging of the 
Cocca-1A, -2A, -3A, -6A, and -3B clones after 48 hours of culture (200X magnification).  (F) 
Phase contrast, 200X magnification of the clone 6A after 3 months of continuous culture. (G-I) 
Phase contrast, 200X magnification of the clone 6A after 6-, 12- months, and 2 yrs of continuous 
culture. 
 
1.4 Purpose 
The Cocca-6A cell were isolated, characterized and cultured from a biopsy of a 
spontaneous fibrosarcoma taken from a domestic female calico cat, Cocca.  Because the 
prognosis of such tumors continues to be poor, I compared the effects of single and combinatorial 
gene therapy using replication deficient adenoviruses expressing RB/p105, RBL2/p130, p53, p18, 
p19, p21waf-1, p27kip-1, pTEN, Mda-7/IL-24, and Ras-DN.  I also studied the effects of 
conditionally replication-competent adenovirus (CRCA) overexpressing immunostimulatory 
proteins such as IFN-γ or Mda-7/IL-24 and the combination of the above viral vectors to identify 
potential cellular targets for the treatment of this tumor. 
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Chapter II: Material and Methods 
2.1 Cell Culture 
Cocca-6A cells were grown with RPMI-1640 (Hyclone, Waltham, MA) medium 
supplemented with 10% fetal bovine serum (Hyclone, Waltham, MA), 100 µg/mL 
penicillin, and 100 µg/mL streptomycin (both from Hyclone, Waltham, MA)  at 37ᴼC in 
a water-saturated atmosphere of 95% air and 5% CO2. Cells were detached from the 
culturing dishes with 0.25% trypsin under aseptic conditions. The human embryonic 
kidney cell line HEK-293 was purchased from ATCC (CRL-1573) and was cultured in 
D-MEM supplemented with 10% FBS, L-Glutamine, 1% Penicillin and Streptomycin all 
from Invitrogen Life Technologies, USA, in 95% air and 5% carbon dioxide (CO2) at 
37°C.  Feline Skeletal Muscle Cells (FSkMC) isolated from the limbal skeletal muscle 
were purchased from CellApplication (F-150-05) and were grown in Feline Skeletal 
Muscle Cell Growth Medium (F-151-500) (CellApplication, San Diego, CA) in 95% air 
and 5% carbon dioxide (CO2) at 37°C. 
 
2.2 Karyotype Analysis 
Colchicine and its derivative, colcemid, are well known inhibitors of mitosis that 
interfere with the structure of the mitotic spindle; they have long been used for obtaining 
synchronized mitotic cell populations [28]. Colcemid was added to logarithmically 
growing cell cultures, followed by incubation for 20 min at 37°C.  The cells were 
harvested with trypsin and incubated for 12 min at 37°C in a hypotonic solution 
containing 0.9% Sodium Citrate.  After centrifugation, the pellet was fixed in three 
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changes of fresh methanol-glacial acetic acid (3:1, v/v).  The fixed cells were dropped on 
pre-chilled (-20ᴼC) pre-cleaned glass slides and air-dried.  Chromosome spreads were 
"aged" at 60°C for 24 hours, subsequently stained in Giemsa for chromosome counts, and 
identification.  A minimum of 100 spreads was evaluated for modal chromosome 
number.  
 
2.3 Semi-quantitative genomic PCR analysis 
Genomic DNA extraction was conducted as previously described [29] on HEK-
293, FSkMC, and Cocca-6a cells. DNA was extracted with genomic lysis buffer and 
proteinase k in 50ᴼC water bath. DNA was separated with phenol and chloroform. Finally 
DNA was precipitated with 10M ammonium acetate and ethanol. Genomic DNA was 
treated with RNAse-A before conducting PCR.  Primers for p53 were as follows: p53-F 
5’-TAC-TCC-CCT-GCC-CTC-AA-3’; p53-R 5’-GGA-GTC-TTC-CAG-TGT-GAT-GA-
3’ [30].  Primers for hypoxanthine phosphoribosyltransferase (HPRT) were as follows: 
HPRT-F 5’-ACT-GTA-ATG-ACC-AGT-CAA-CAG-GGG-3’; HPRT-R 5’-TGT-ATC-
CAA-CAC-TTC-GAG-GAG-TCC-3’ [31].  PCR reactions were done on Techne TC-
3000G PCR Thermal Cycler.  PCR reactions were conducted using the Phusion High-
Fidelity DNA polymerase kit (Thermo Scientific, F-530).  The denaturation step of the 
cycle is where DNA was heated to 98°C for 10sec.  Annealing temperature for p53 
primers was 60°C, and for HPRT primers was 65°C. The extension step was performed at 
72°C for 30sec. The PCR was run for 35 cycles. The Image-J software (NIH) was used to 
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quantify the densitometric signal acquired by a Fotodyne computerized imaging system 
(Fotodyne, Hartland, WI). 
 
2.4 Cytological Observations 
The cells were examined under an inverted Olympus IX70 microscope (Olympus 
America, Inc. Melville, NY).  Fluorescence images were captured with Sensicam QE 
camera (Cooke Co., Auburn Hills, MI) and managed with the SlideBook 3.0 software 
(Intelligent Imaging Innovations Inc., Denver, CO). 
 
2.5 Adenoviral production and purification 
Ad.CMV (non-coding or empty virus with a Cytomegalovirus (CMV) promoter), 
Ad.GFP and Ad.p53 viruses were generated using the AdEasy system (Carlsbad, CA). 
The Ad.RB/p105 viruses were provided by Dr. Juan Fueyo (M.D. Anderson Cancer 
Center, The University of Texas), the Ad.pTEN by Dr. Chris Kontos (Duke University, 
Durham, NC) and the Ad.p18, Ad.p19, Ad.p21waf-1, and Ad.p27kip-1 viruses by Dr. 
Frank L. Graham (McMaster University, Hamilton, Ontario Canada). CTV-Mda7 
(Ad.PEG-E1A-mda-7), CTV-IFN-γ (Ad.PEG-E1A-IFN-γ), and Ad.mda-7/IL-24 were 
provided by Dr. Paul Fisher (Virginia Commonwealth University, Richmond VA).  The 
Ad.Ras-DN (dominant negative (116Y) v-H-RAS mutant) and Ad.p130 (RBL2/p130) 
viruses were purchased from Vector BioLabs (Philadelphia, PA). All the Adenoviruses 
were amplified, tittered and purified as previously described [23, 32].  Each viral stock 
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was propagated and purified from 293 cell cultures. Cells were harvested 24-36 hours 
after infection, pelleted and resuspended in heat-inactivated media. 293 cells were lysed 
by a three-freeze/thaw cycle method. Cell debris was removed. Viruses were purified by 
chromatography followed by dialysis. Viruses are aliquoted and stored at -80°C. Viral 
titers were determined by a plaque assay. Adenovirus transductions were performed using 
50 MOI Adenoviruses (Ads), in RPMI-1640 media with 2% Fetaclone-III heat-
inactivated FBS (Hyclone, Thermo Scientific, Waltham, MA). Combinations of 
adenoviral transductions were done using a total of 50 MOI viruses.  After 16h, the media 
were replaced with fresh media and cells were collected after 24- or 48-hours. Feline 
Skeletal Muscle Cells (FSkMC) isolated from the limbal skeletal muscle were used to investigate 
the effects of the various adenoviral constructs in normal cells. 
 
2.6 Western blot analysis 
Western blot analysis was conducted as previously described [23, 33]. Cells were 
lysed on ice for 1hr with lysis buffer. Protein concentration was measured using 
Bradford’s reagent on an Eppendorf Biophotometer. The protein 50 μg of total cell 
extracts were subjected to western blot analysis. SDS-PAGE was run using 8-12% bis-
acrylamide gel at room temperature. 20 μL of total proteins plus loading buffer were 
loaded in each well. Samples were transferred onto a nitrocellulose membrane. To detect 
proteins the membranes was blocked with 5%Milk-TBST overnight at 4ᴼC and incubated 
with primary antibodies for 2hr at room temperature with constant motion on a an orbital 
shaker while overnight incubation for proteins below 50kda. The membranes were 
washed with TBST to remove excess primary antibodies. Incubation for 45 minutes with 
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1/5000 anti-mouse or 1/10000 anti-rabbit secondary antibodies diluted in TBST followed. 
Immunodetection was performed using the enhanced chemiluminescence (ECL) system 
(Amersham, IL) according to the manufacturer’s instructions. Western blot analyses with 
antibodies against the targeted proteins were performed to validate successful viral 
transfection of the cells. 
The following primary antibodies were used: mouse monoclonal antibodies 
against p53 (DO-1) cat#sc-126 (1:500), p18 cat#sc-9965 (1:100), p19 cat#sc-65594 
(1:100), RB/p105 cat#sc-102 (1:250) (Santa Cruz Biotechnology, Santa Cruz, CA), Mda-
7/IL-24 k101 (GenHunter Corporation), β-actin cat#A3853 (1:1,500) (Sigma Aldrich); 
mouse polyclonal IFN-γ cat#H00003458-801 (Abnova); and rabbit polyclonal antibodies 
against RBL2/p130 cat#sc-317 (1:250), p21 cat#sc-397 (1:125), p27 cat#sc-528 (1:500), 
H-Ras cat#sc-520 (1:500) (Santa Cruz Biotechnology, Santa Cruz, CA), pTEN cat#9552 
(1:500) (Cell Signaling) and GFP cat#632377 (1:500) (BD Bioscience).  
 
2.7 Flow Cytometry Assay 
Adenoviral transduced Cocca-6A cells were trypsinized and collected. Cells were 
centrifuged at 5000 rpm, washed and suspended in 1% FCS-PBS. This step was repeated 
three times. After several washings in 1mL of 1% FCS-PBS the cells were fixed with pre-
chilled (-20ᴼC) 70% ethanol. Samples were fixed and stored at 4ᴼC. The samples were 
re-suspended in 1% FCS-PBS then incubated at 37ᴼC with propidium iodide (PI) and 
RNAse A for 30 min.  Samples were prepared, run by a FACS Aria (BD Bioscience, San 
Jose, CA) and analyzed using the flow cytometry analysis software Flow-Jo (Flow-Jo, 
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Ashland, OR) as previously described [33]. Single cells population was gated and an FL2 
area histogram was drawn and formatted to show only the events inside the single cell 
region. 
 
2.8 Annexin-V assay 
Apoptotic cells were analyzed with fluorescein isothiocyanate (FITC) conjugated 
to Annexin-V antibody and Propidium Iodide (PI) from the Annexin-V/FITC Kit (Bender 
MedSystems, Burlingame, CA) following manufacturer's instructions. Cells were 
trypsinized and washed with PBS. Cells were centrifuge and re-suspended in binding 
buffer. Apoptosis analysis was done using the Annexin-V assay on the Flow Cytometer. 
Cytometry was operated with a FACS Aria (BD Bioscience, San Jose, CA).  Annexin-V 
assay experiment was repeated three times and was run as triplicate of technical repeats. 
Statistical analysis was performed with IBM SPSS statistic software. 
 
2.9 Ethics statement 
Animal approval from IACUC was not required in this study.  The procedures 
performed on the animal were conducted as part of veterinarian standard of care 
procedures. 
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2.10 Statistical analysis 
Microsoft Excel was used to plot the mean and standard deviation graphs. 
Statistical analysis was performed using the IBM SPSS statistical software.  Comparison 
of Sub-G1 (apoptotic fraction) populations on adenoviral transduced groups and 
comparison of cell death by Annexin-V on adenoviral transduced groups were conducted 
using an ANOVA test with post hoc test of Dunnett’s T3.  p values of less than 0.05 were 
considered statistically significant.  
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Chapter III: Results 
3.1 Karyotype Analysis  
Karyotype of the domestic cat (Felis catus) had been reported by several 
investigators [34-36]. According to them the chromosome number of the domestic cat is 
2n, 38 [37]. Chromosome counts showed that the Cocca-6A cells were nearly diploid, 
with a chromosome number of 37. Metaphase cells obtained from early passage 5 and 
late passage 100 had the same chromosome numbers of 37 (Fig.5).   
In a normal karyotype of the domestic cat there are eighteen autosome pairs 
classified into A to F groups; the group A is consisted of 3 large submetacentric pairs (A-
1 to A-3); the group B of 4 large subtelocentric pairs (B-1 to B-4); the group C of 2 large 
metacentric pairs (C-1 and C-2); the group D of 4 considerably small subtelocentric pairs 
(D-1 to D-4); the group E of 3 small metacentric pairs (E-1 to E-3) and the group F of 2 
small acrocentric pairs (F-1 and F-2) [37]. The X was metacentric corresponding in size 
to the C group, while the Y was of small subtelocentric structure [37]. Chromosomes 
were paired following a Giemsa block staining showing the lack of one of the E1 
chromosomes where, among other genes, the p53 gene product maps in feline (Fig. 5). 
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Figure 5. Karyotype of the feline fibrosarcoma Cocca-6A cells. Oil immersion microphotograph 
(1000X magnification) of the unbanded karyotype of spotted metaphases Giemsa block stained 
from a representative colchicine treatment of the Cocca-6A cells. The Cocca-6A cells show the 
presence of aneuploidy with 37 chromosomes. The Cocca-6A cells show the absence of one of 
the E1 chromosomes.  
  
3.2 Semi-quantitative genomic DNA PCR 
Semi-quantitative genomic DNA PCR was performed using primers against p53, 
which has been previously identified on chromosome E1.  The p53 primers used 
amplified also part of the human p53 (HEK-293 cells) as shown in Figure 6.  The PCR 
products of genomic p53 amplified from Cocca-6A cells was less abundant in 
comparison to the PCR product from the feline skeletal muscle cells (FSkMC).  Results 
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were normalized to the hypoxanthine phosphoribosyltransferase (HPRT) control from the 
X chromosomes, which amplified an equal amount of PCR product. 
 
Figure 6. Semi-quantitative PCR of p53 and hypoxanthine phosphoribosyltransferase (HPRT) 
gene in human HEK-293, feline FSkMC and Cocca-6A cells. 
 
3.3 Effects of Adenoviral gene transfer on cat fibrosarcoma 
Various proteins involved in the cell cycle and apoptosis pathways such as Rb/p105, 
p130, p53, p18, p19, p21waf-1, p27kip-1, pTEN, and the dominant negative H-RAS Mutant 
(116Y) (RasDN), as well as of two immunostimulatory cytokines (Mda-7/IL-24, and IFN-γ)  
were tested by transducing them into the feline cells using adenoviruses. Cocca-6A cells were 
transduced using a total of 50 MOIs of the various adenoviruses. An adenovirus carrying an 
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empty CMV promoter and Adenovirus containing the green fluorescence protein (GFP) (Fig. 7A 
and B) were used as controls. The transduced cells with the adenovirus carrying the green 
fluorescence protein (GFP) showed a normal cell cycle profile, with a small fraction of the cells 
in sub-G1 phase (2.7%), similar to that of Ad.CMV transduced and to untransduced cells (Fig. 
7C). 
 
 
Figure 7.  Effects on the feline fibrosarcoma Cocca-6A cells following Adenoviral gene transfer.  
(A) Phase contrast imaging of Ad.CMV transduced Cocca-6A control cells at 24 hours (200X 
magnification).  (B)  Fluorescence imaging (200X magnification) of the Ad.GFP-transduced 
Cocca-6A control cells at 24 hours.  (C)  Flow-cytometric diagram of Ad.GFP transduction of 
Cocca-6A cells (50 MOI, 24-hours after transduction).   
 
3.4 Cytological Observations after Adenoviral Gene Transfer 
Proteins such as Rb/p105, dominant negative H-RAS Mutant (116Y) (RasDN), as well as 
of two immunostimulatory cytokines (Mda-7/IL-24, and IFN-γ) that were transduced using a total 
of 50 MOIs were expressed into the feline cells using adenoviruses. These transduced cells 
showed visible cytopathic effect (Fig. 8A-E). While other transduced proteins such as p130, p53, 
p18, p19, p21waf-1, p27kip-1 and pTEN did not elicit an effect on the feline fibrosarcoma cells 
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(see Fig. 8F-L).
 
Figure 8.  Effects on the feline fibrosarcoma Cocca-6A cells following Adenoviral gene transfer.  
(A-L) Phase contrast imaging (200X magnification) of Ad.Rb/p105, Ad.Ras-DN, Ad.mda7/IL-
24, CTV/IFN-γ, CTV-mda7/IL-24, Ad.pTEN, Ad.p53, Ad.p130, Ad.p18, Ad.p19, Ad.p21 and 
Ad.p27 transduced Cocca-6A cells (50 MOI, 24-hours after transduction). 
22 
 
3.5 Effects of single and combination of Adenoviral gene transfer on the feline fibrosarcoma 
cells Cocca-6A.   
There was an increase in the sub-G1 fraction of Cocca-6A cells transduced with 
Ad.RB/p105 (p=0.257), Ad.Ras-DN (p=0.135), Ad.Mda7/IL-24 (p=0.243), CTV.mda-7/IL-24 
(p=0.573), or CTV.IFN-γ (p=0.185) (Figs. 9 c-g and Table 1), but not with Ad.p53, Ad.p130, 
Ad.p18, Ad.p19, Ad.p21waf-1, Ad.p27kip-1, or Ad.pTEN (Figs. 9 a-g and Table 1) with p>0.05, 
when compared to the Ad-CMV (Table 1) or to Ad-GFP mock transduced cells (Fig. 9 B and 
Table 1).  Because some of the tested adenoviruses (Ads) did not elicit an effect on the feline 
fibrosarcoma cells (see Fig. 8), the combinatorial effects of Ads carrying proteins that elicited a 
more profound response (Fig. 9 c-g and see Fig. 8) was tested.  A propidium iodide-flow 
cytometry analysis of cells transduced with 50 MOIs of various combinations of double or triple 
transductions using Ads carrying Ad.RB/p105, Ad.Ras-DN, Ad.mda-7/IL24, CTV.mda-7/IL24 or 
CTV.IFN-γ demonstrated a considerable increase of the apoptotic fraction (Sub-G1) in the 
various samples examined.  
Figure 9 depicts the contrast phase microscope images of the Cocca-6A cells and the cell 
cycle profiles following combined adenoviral transduction treatments, which were analyzed using 
an ANOVA (Analysis of Variance) with a post hoc test of Dunnett’s T3 to compare the Sub-G1 
(apoptotic fraction) populations on several adenoviral transduced groups (Table 1). The following 
adenoviral combinations showed an increased amount of Sub-G1 population (Fig.9h-q): 
Ad.Rb/p105 and Ad.Ras-DN (Fig.9h), Ad.Rb/p105 and Ad.mda7/IL24 (Fig.9i), Ad.Rb/p105 and 
Ad.CTV-Mda-7/IL24 (Fig.9j), Ad.Rb/p105 and Ad-CTV IFN-γ (Fig.9k), Ad.Ras-DN and 
Ad.Mda-7/IL-24 (Fig.9l), Ad.Ras-DN and Ad.CTV-Mda-7/IL-24 (Fig.9m), Ad.Ras-DN and Ad-
CTV-IFN-γ (Fig.9n), Ad.Rb/p105 and Ad.Ras-DN and Ad.Mda-7/IL24 (Fig.9o), Ad.Rb/p105 and 
Ad.Ras-DN and Ad.CTV-Mda-7/IL24 (Fig.9p), Ad.Rb/p105 and Ad.Ras-DN and Ad-CTV-IFN-γ 
(Fig.9q).  
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Figure 9. The effects of the combination of Adenoviral gene transfer on the feline 
fibrosarcoma cells Cocca-6A.  Every panel shows the phase contrast imaging (200X 
magnification, 24-hours post transduction) and the propidium iodide flow cytometry analysis of 
Cocca-6A cells transduced with 50 MOIs of various combinations of double or triple 
transductions using Ads carrying Ad.RB/p105, Ad.Ras-DN, Ad.mda-7/IL24, CTV.mda-7/IL24 or 
CTV.IFNγ.  
(a-g) Single adenoviral transduction and controls: (a) Control untransduced Cocca-6A cells.  (b) 
Ad.GFP, (c) Ad.Rb/p105, (d) Ad.Ras-DN, (e) Ad.Mda7/IL-24, (f) CTV.Mda7/IL-24, (g) 
CTV.IFNγ transduced Cocca-6A cells.   
(h-q) Combinations of double or triple adenoviral transductions: (h) Ad.Rb/p105 + Ad.Ras-DN, 
(i) Ad.Rb/p105 + Ad.Mda7/IL-24, (j) Ad.Rb/p105 + CTV.Mda7/IL-24, (k) Ad.Rb/p105 + 
CTV.IFNγ, (l) Ad.Ras-DN + Ad.Mda7/IL-24, (m) Ad.Ras-DN + CTV.Mda7/IL-24, (n) Ad.Ras-
DN + CTV.IFNγ, (o) Ad.Rb/p105 + Ad.Ras-DN + Ad.mda7/IL-24, (p) Ad.Rb/p105 + Ad.Ras-
DN + CTV.mda7/IL-24, (q) Ad.Rb/p105 + Ad.Ras-DN + Ad.CTV.IFNγ transduced Cocca-6A 
cells. 
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(I) Groups (J) Groups 
Mean 
Difference (I-J) p value 
Control CMV .6666667 1.000 
GFP -.8333333 1.000 
PTEN -3.2333333 1.000 
p18 -2.6000000 1.000 
p19 .8000000 1.000 
p21 -3.6666667 .998 
p27 -4.2333333 .989 
p53 -4.5666667 .980 
RB2 -4.2666667 1.000 
RB -25.3333333 .257 
Ras DN -39.6000000 .135 
Ad Mda7 -18.6000000 .243 
CTV Mda7 -15.3666667 .573 
CTV IFNG -18.8333333 .185 
RB + Ras DN -21.4666667 .323 
RB + Mda7 -15.4333333 .634 
RB + CTV Mda7 -44.4666667 .345 
RB + CTV IFNG -48.5666667 .050 
Ras DN + Mda7 -14.6666667 .280 
Ras DN + CTV Mda7 -53.3666667 .057 
Ras DN + CTV IFNG -52.8000000* .011 
RB + Ras DN + Mda7 -11.1666667 .992 
RB + Ras DN + CTV Mda7 -63.9333333* .005 
RB + Ras DN + CTV IFNG -62.8666667* .007 
 
Table 1. ANOVA (Analysis of Variance) significance table with a Post Hoc Dunnett’s T3 test for 
a propidium iodide flow cytometry analysis of feline fibrosarcoma cells transduced with various 
adenoviruses carrying pro-apoptotic and cell cycle regulating genes.* The mean difference is 
significant at the 0.05 level. 
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3.6 Annexin V staining for cell death 
The apoptotic rate of the transduced cells was quantified by assessing the samples 
Annexin-V expression. The analyzed cells were allocated in a quadrant diagram according to 
their DNA content and the presence of Annexin-V on the extracellular cell membrane during 
apoptosis. Statistical analysis was run on Annexin-V triplicates of three separate experiments 
using IBM SPSS statistic software for an ANOVA on dead cells with a post hoc test of Dunnett’s 
T3 post hoc test (Fig. 10 and Table 2). Cocca-6A cells undergoing apoptosis and necrosis were 
collectively called as dead cells.  Ad.CMV (non-coding or empty virus) transduced cells were 
compared to mock untransduced cells and no statistically difference was observed (p=0.585, 
Table 2).   All samples were compared to the Ad.CMV transduced negative control. Mean and 
standard deviation from Annexin-V experiment was calculated for each adenoviral treated 
groups. Groups transduced with single Ad.Mda7, Ad.CTV-Mda7 and Ad.CTV-IFNγ or double 
gene transfer of Ad.Rb + Ad.Ras DN, Ad.Ras DN + AdCTV.Mda7, Ad.Ras DN + Ad.CTV.IFNγ 
showed high statistical significant difference against the control (p<0.05, Table 2).   
Cocca-6A cells treated with triple combination of Ad.RB, Ad.Ras DN and Ad.Mda7 gene 
transfer showed 44.13% ± 3.57 S.D. of dead cells with a p value of 0.006.  Triple combination of 
Ad.RB, Ad.Ras DN and Ad.CTV-Mda7 showed the highest percentage of dead cells (51.63% ± 
4.30S.D.) with a p value of 0.0001. Amongst the double combinational treatments, Ad.RB with 
Ad.Ras DN (44.03% ± 3.37S.D.); and Ad.Ras DN with Ad.CTV-Mda7 (46% ± 3.18S.D.) showed 
the highest percentage of dead cells.  Amongst single adenoviral transductions the Ad.CTV-Mda7 
(43.87% ± 6.17S.D.) group had the highest percentage of dead cells.  Each adenoviral 
transduction groups showed high percentage of cell death in comparison to the control (Table 2).  
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Figure 10. Apoptotic rate of Cocca-6A cells following Adenoviral gene transfer measured by 
Annexin-V assay. On the ordinate are indicated the percentages of dead cells following 
adenoviral transductions. On the abscissa are indicated the different adenoviruses used.  Cells 
were stained using an Annexin-V fluorescence kit and were run on a BD scientific Facs-Aria flow 
cytometer. 
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(I) Group Name (J) Group Name 
Mean 
Difference (I-J) p value 
Control CMV -5.46667 .585 
RB -35.16667 .063 
Ras DN -26.20000 .084 
Mda7 -28.30000* .030 
CTV Mda7 -37.83333 .050 
CTV IFNG -27.33333* .048 
RB + Ras DN -38.00000* .004 
RB + Mda7 -32.23333 .075 
RB + CTV Mda7 -26.10000 .099 
RB + CTV IFNG -24.26667 .081 
Ras DN + Mda7 -34.00000 .055 
Ras DN + CTV Mda7 -39.96667* .003 
Ras DN + CTV IFNG -33.33333* .005 
RB + Ras DN + Mda7 -38.10000* .006 
RB + Ras DN + CTV 
Mda7 
-46.93333* .000 
RB + Ras DN + CTV 
IFNG 
-37.70000 .160 
 
Table 2. ANOVA (Analysis of Variance) significance table with a Post Hoc Dunnett’s T3 test for 
Annexin-V assay on feline fibrosarcoma cells transduced with various adenoviruses carrying pro-
apoptotic and cell cycle regulating genes. * The mean difference is significant at the 0.05 level. 
 
3.7 Effect of Adenoviruses on normal feline cells 
Feline Skeletal Muscle Cells (FSkMC) isolated from the limbal skeletal muscle were 
used to investigate the effects of the various adenoviral constructs in normal cells. The apoptotic 
rate of the transduced normal cells was quantified by assessing the samples Annexin-V 
expression. Statistical analysis was run on Annexin-V triplicates of three separate experiments 
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using IBM SPSS statistic software for an ANOVA on dead cells with a post hoc test of Dunnett’s 
T3 post hoc test (Fig. 11 and Table 3).  
Ad.CMV transduced FSkMC cells were compared to mock untransduced FSkMC cells 
and no statistically difference was observed (Table 3, p>0.05).   All samples were compared to 
the Ad.CMV transduced negative control. Mean and standard deviation from Annexin-V 
experiment was calculated for each adenoviral treated groups.  All groups transduced with any of 
the adenoviruses carrying pro-apoptotic or cell cycle genes showed no statistical significant 
difference against the Ad.CMV transfected control (Table 3).  
       
Figure 11. Apoptotic rate of FSkMC cells following Adenoviral gene therapy measured by 
Annexin-V assay. On the ordinate are indicated the percentages of dead cells following 
adenoviral transductions.  On the abscissa are indicated the different adenoviruses used.  To 
quantify the apoptotic rate of the transduced normal cells the samples were assayed by assessing 
Annexin-V expression using Annexin-V fluorescence kit and were run on a BD scientific Facs-
Aria flow cytometer. Statistical analysis was run on Annexin-V triplicates of three separate 
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experiments using IBM SPSS statistic software for an ANOVA on dead cells with a post hoc test 
of Dunnett’s T3 post hoc test. No statistical significance was observed for normal FSkMC cells. 
(I) Groups (J) Groups 
Mean 
Difference (I-J) p value 
CMV p18 -.70000 1.000 
p19 -2.96667 .473 
p21 -26.50000 .097 
p27 -11.36667 .733 
p53 -24.06667 .202 
p130 -.20000 1.000 
RB -18.23333 .150 
Ras DN -5.83333 .914 
pTEN -5.36667 .959 
IFNG -33.00000 .064 
CTV Mda7 3.36667 .986 
Mda7 -5.86667 .944 
 
Table 3.  ANOVA (Analysis of Variance) significance table with a Post Hoc Dunnett’s T3 test 
for Annexin-V assay on feline skeletal muscle (FSkMC) cells transduced with various 
adenoviruses carrying pro-apoptotic and cell cycle regulating genes. Statistical analysis was run 
on Annexin-V triplicates of three separate experiments using IBM SPSS statistic software for an 
ANOVA on dead cells with a post hoc test of Dunnett’s T3 post hoc test. * The mean difference 
is significant at the 0.05 level. 
 
3.8 Verification of protein expression by western blots 
To verify the expression of the transduced adenoviral vectors, western blot analysis was 
performed forty-eight hours following transduction with the various adenoviral vectors.  Figure 
12 shows that the various adenoviruses successfully transferred and expressed the targeted 
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transgene in the Cocca-6A cells.  Antibodies against p21, pRb/p105, p130, and Beta Actin used in 
the western blot analysis of the transfected and untransfected Cocca-6A cells cross-reacted with 
feline species (control lane).   
 
Figure 12. Western blot analysis of Cocca-6A cell lysates following adenoviral transduction.  
On the left lane are loaded control Cocca-6A cells. In the lane on right are loaded the transduced 
Cocca-6A cells.  Anti-beta-actin was used as a loading control.  50µg of total lysates were run in 
SDS polyacrylamide gels.  On the left side are indicated the different adenoviral transductions. 
Feline cross-reactivity of the antibodies, which were raised against human proteins was 
verified by performing a series of western blot analysis using human HEK-293 cells and Feline 
Skeletal Muscle Cells (FSkMC) as controls (Figure 13).  Interestingly, antibodies raised against 
the human p21, p53, pRb and p130 proteins cross-reacted with feline proteins from lysates of 
normal FSkMC cells. The p53 antibody (clone DO-1), which has been reported to cross-react 
with cat p53 [38], did show only a weak band in the Cocca-6A cells compared to the normal 
FSkMC cells (Figure 13).   
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Figure 13. Western blot analysis of HEK-293, FSkMC and Cocca-6A cell lysates.  On the left 
lane are loaded control human embryonic kidney HEK-293 cells and the central lane are loaded 
normal feline muscle skeletal cells. In the lane on right are loaded the Cocca-6A cells.  Anti beta-
actin was used as a loading control.  50µg of total lysates were run in SDS polyacrylamide gels.   
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Chapter IV: Discussion 
Despite aggressive pre- or postoperative treatment, feline fibrosarcomas have high 
recurrence rates.  Spontaneous feline fibrosarcomas are rare and have not been associated with a 
vaccination site [39-42].  A retrospective study of 195 feline sarcomas showed that 170 (87.2%) 
were fibrosarcomas [43].  In this work it was also noted that cats with vaccination site (VS) 
fibrosarcomas were younger (median = 8 years) than cats with non-vaccination site (NVS) 
fibrosarcomas (median = 11 years), but there was no such association with breed, sex, or "neuter 
status"[43].  Although feline fibrosarcoma doesn’t appear to be an infrequent disease, no 
established fibrosarcoma cell lines of spontaneous origin are commercially available causing 
further difficulties in testing appropriate and more effective treatments for this disease. A 
recurring spontaneous fibrosarcoma cell line was established from domestic cat as a model to test 
the efficiency of gene transfer for the treatment of this aggressive cancer given the lack of other 
therapeutic options.   
Recently, recombinant human proteins such as interleukin-2 (h-IL-2) has been used as a 
treatment option for cats with fibrosarcoma [7, 17].  It has been shown that feline fibrosarcomas 
treated with human IL-2 relapse less frequently and patients survive longer than control animals 
treated by surgery and radiotherapy alone suggesting that gene transfer approach using human 
gene products could be a suitable treatment option for this disease [7, 17].  In this study, I tested 
and compared the ability of a series of adenoviruses carrying various human proteins that are 
involved in regulation of the cell cycle or apoptosis such as Rb/p105, p130, p53, p18, p19, 
p21waf-1, p27kip-1, pTEN, and the dominant negative H-RAS Mutant (116Y) (Ras DN).  The 
effects of two immunostimolatory human cytokines (Mda-7/IL-24, and IFN-γ) that were 
transferred and expressed into the feline fibrosarcoma cells using adenoviruses were also tested. 
Interestingly, no cell cycle modifications were observed when transducing the feline fibrosarcoma 
cells with single transfer of adenoviruses expressing human p53, p130, p18, p19, p21waf-1, 
p27kip-1, or pTEN compared to the parental control or to Ad-GFP mock transduced cells (data 
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not shown).  Despite successful human protein expression in feline cells as confirmed by western 
blot analysis (Fig. 12), a set of cell cycle/apoptosis regulators failed to elicit an effect on the 
growth and viability of the feline cells.  The reason behind this occurrence was not further 
investigated. One possible explanation is that the amino-acid sequences of the human proteins 
used in the adenoviral transduction assays could differ so much from the feline proteins to not be 
able to elicit an effect on the feline cell cycle/apoptosis machinery. 
 In a recent published report, the presence of numerical chromosomal and centrosomal 
aberrations in 5 vaccine-associated feline fibrosarcoma cell lines and in a fetal dermal fibroblast 
cell line as a control was determined.  It was found that the number of chromosomes deviated 
abnormally from the normal feline chromosome number of 2n = 38, ranging from 19 to 155 
chromosomes per cell [44].  Interestingly chromosomal counts showed that the Cocca-6A cells 
were nearly diploid, with a chromosome number of 37 (normal cat; 2n = 38).  Metaphase cells 
obtained at passage 100 maintained the same chromosome numbers as earlier passages (Fig. 5).  
Chromosome studies provide one major approach to understanding of mechanisms 
related to cancer. Chromosome alterations may act both ways: they may result in mutations of 
certain genes or else they may result in different gene regulation and expression [45].  It has been 
previously shown that feline tumors are often associated with mutations in proteins involved in 
cellular proliferation control. Previous studies have also shown aberrations such as deleted B2, 
one marker F1, two reciprocal translocations (t (A2q;E3q) and t(A1q; B4q) [46],  and 
translocation between chromosomes E1 and A1 (t(E1p; A1p) [5]. In my study, chromosomes 
were paired following a Giemsa block staining showing the lack of one of the E1 chromosomes 
(Fig. 5).   
Submicroscopic changes at the DNA level, such as base changes or small undetected 
deletions, do occur in feline fibrosarcoma [46]. Mutations in the p53 gene have been found 
associated with various tumors in people and animals including fibrosarcomas [30, 44, 47, 48]. In 
one fibrosarcoma, a mutation GAG AAG (glutamic acid lysine) in codon 180; in another 
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there was a mutation CGG TGG (arginine  tryptophan) in codon 248 has been observed [30]. 
The p53 gene product, that maps on feline chromosome E1 [49], is a multifunctional transcription 
factor that regulates induction of apoptosis in cells with irretrievably damaged DNA, thus 
preventing propagation of damaged DNA.   More than 50% of tumors in people, including 
various sarcomas, have p53 gene mutations.  The p53 gene is located on the E1 chromosome but 
Cocca-6A fibrosarcoma cells lack one of the E1 chromosomes.  To test the presence p53 a semi-
quantitative genomic DNA PCR was performed which demonstrated that there is a lower amount 
of p53 genomic DNA in the Cocca-6A in comparison to the normal FSkMC cells. 
 Adenovirus carrying human p53 was transduced to modulate the cell cycle of these 
aggressively growing feline fibrosarcoma cells.  Surprisingly, adenoviral mediated 
overexpression and gene replacement using human wild-type p53 did not elicit any effects in the 
Cocca-6A feline fibrosarcoma cell line.  The lack of cell cycle effects following forced 
expression of human p53 in the Cocca-6A cells could be due to differences between the human 
and feline p53 genes, in fact in has been reported that the amino-acid sequence of the feline p53 
gene is 82.1% and 74.9% similar to the human and mouse counterparts, respectively [49]. 
 Other cell cycle arrest and regulator proteins such as Retinoblastoma protein pRb/p105, 
p21 (also called waf-1, CIP-1, and SDII) and p27 (also called Kip-1) was transduced in Cocca-6A 
cells. Only pRb protein elicited any cell death. The RB/p105 gene has been found mutated in the 
majority of human tumors [50, 51]. Unfortunately, there is no data available regarding mutations 
in the RB/p105 gene in domestic cat tumors.  Interestingly, the expression of human RB/p105 
showed relatively high levels of cell death (although not statistically significant) in the Cocca-6A 
feline fibrosarcoma cell line, which was instead refractory to the effects of p53. 
 In order to find the most effective gene transfer tool, the effects of another adenoviral 
transduction of a mutant form of Ras (RAS-DN) in Cocca-6A cells was performed. Single 
expression of Ras-DN caused high levels of cell death in the feline fibrosarcoma cell line, 
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although not statistically significant.  Ras is a protein of the GTPase family that is involved in 
signal transduction, cell growth and apoptosis [52]. It has been also shown that in regulating 
apoptosis Ras has many faces. It has both negative and positive effects depending on the 
stimulation and cell type. The responses of cells to Ras signaling depends on the level of Ras 
expression, the activity of various pathways, and functional cell cycle check points [53].  In 
fibroblasts in particular, the pathway downstream of activating Ras has been shown to involve the 
Raf/MAP kinase pathway, and to function in a p53 dependent manner, by increasing the levels of 
p16kip-4 and p21waf-1 [53]. Additionally, utilization of dominant inhibitory mutants such as, H-Ras 
DN, that specifically blocks the activation of all three isoforms of Ras wild-type proteins. [54]. 
When Cocca-6A cells were transduced with both Ad.RB and Ad.Ras DN showed higher levels of 
cell death in comparison to single adenoviral transduction, which were found to be statistically 
significant (p<0.05).  
The pro-apoptotic and tumor suppressor properties of Mda-7/IL-24 were also tested by 
transducing them in Cocca-6A cells. The Mda-7, melanoma differentiation associated gene 7/IL-
24, is a secreted cytokine with selective activity against cancer, with anti-apoptotic and anti-
angiogenic ability. Based on sequence homology, chromosomal localization, and its functional 
properties, the mda-7 gene is now classified as a member of the IL-10 family of cytokines and 
named IL-24 [55-58]. The tumor suppressing ability of mda-7/IL-24 is well established and is 
independent of the status of other tumor suppressor genes, such as p53 and Rb, or apoptosis 
regulating genes, such as bax or caspases, in tumor cells [59]. Recently, a novel adenoviral vector 
has been created in which E1A is controlled by the PEG-3 (progression elevated-3 gene) 
promoter, which is a promoter that is active only in cancer cells, enabling the Adenovirus to 
replicate selectively in cancer cells [21, 60, 61].  This conditionally replicating Adenovirus is also 
called Cancer Terminator Virus (CTV).  The CTVs have been engineered to contain sequences 
for anti-tumoral proteins such as Mda-7 or IFN-γ.   
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Transduction of the feline fibrosarcoma cells with the CTVs elicited the greatest negative 
effects on cellular viability (p<0.05), due to cellular combined effects of mda-7 or IFN- γ and the 
lytic properties of the adenoviral particles.  The observed tumor cell killing effects were stronger 
when we transduced the feline fibrosarcoma cells with CTV-Mda7 than with IFN-γ, possibly due 
to the previously demonstrated Mda-7/IL-24 higher pro-apoptotic ability [59].  This property 
maybe the reason for greater cell death when a pro-apoptotic viral cocktail (Rb and Ras-DN) is 
combined with the immunomodulating cytokine Mda-7/IL-24. 
In conclusion, the combinatorial use of Ad.Ras-DN, Ad.Rb and CTV-Mda7/IL-24 genes 
may be the best possible future adjuvant treatment for spontaneous feline fibrosarcoma.  
However, therapy for aggressive feline fibrosarcomas is often insufficient for complete and long-
lasting tumor eradication and more gene transfer studies involving various established feline 
fibrosarcomas should be conducted in order to understand if these viral vectors (Ras-DN, Rb, 
Mda7/IL24) could be applicable regardless of the origin (spontaneous vs. vaccine induced) of 
feline fibrosarcomas. 
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